BioLineRx (NASDAQ:BLRX) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

BioLineRx (NASDAQ:BLRX) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19, Zacks reports. BioLineRx had a negative net margin of 45.34% and a negative return on equity of 49.74%. The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.67 million.

BioLineRx Trading Up 3.2%

BioLineRx stock opened at $3.36 on Monday. BioLineRx has a one year low of $2.30 and a one year high of $14.70. The stock has a market cap of $14.60 million, a PE ratio of -1.39 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.87 and a current ratio of 2.06. The stock has a 50-day moving average of $3.69 and a two-hundred day moving average of $3.98.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.00.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.